Key Findings on Filgotinib Trial for Crohn’s to be Presented at UEG Week

Key Findings on Filgotinib Trial for Crohn’s to be Presented at UEG Week
Galapagos will present endoscopic improvements and other key findings from the FITZROY Phase 2 clinical trial of filgotinib in Crohn’s disease, during United European Gastroenterology Week (UEG Week), Oct. 15-19, in Vienna. Lead investigator Dr. Séverine Vermeire will present the abstract titled “Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn’s disease: final

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *